Lumida
/HCAT
⌘K
Health Catalyst Inc

Health Catalyst Inc

HCAT
$1.70USD↓-1.73%-0.03 today

MARKET CAP

127.9M

P/E (TTM)

8.6x

FWD P/E

—

DAY RANGE

$2 – $2

52W RANGE

$1
$4

AI Summary

Stalk
StalkMedium

HCAT is in a Stage 2 advance with clear higher highs and higher lows and rising short-term EMAs, but price is extended above EMAs and overbought in the short term. Medium-term bias remains bullish after the recent breakout, yet execution should wait for a pullback into the rising 9/20 EMA zone or the lower portion of the breakout range before participation.

  • ↑Q2 revenue $70.5M topped guidance; adjusted gross margin rose to 51% YoY
  • ↑VitalWare divestiture cut $160M debt and $19M in annual interest expense
  • ↓Consensus FY26 EPS cut to –$2.41 and revenue down to $247.4M from $268.2M
Full analysis →

Buying

3

institutions

Selling

3

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL1.84 M3.65 M+-3.30 M-44.0%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY546.71 K1.09 M+479.91 K+1182.4%0.00%
MM

Millennium Management LLC

Q2 2026

BUYNEW516.08 K1.03 M+516.08 K+0.0%0.00%
AC

Aqr Capital Management LLC

Q2 2026

SELL376.59 K749.41 K+-166.66 K+8.6%0.00%
RT

Renaissance Technologies LLC

Q2 2026

BUY349.27 K695.04 K+132.20 K+152.1%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL1.95 K3.82 K+-676.00 K-99.5%0.00%